Ashwagandha and Thyroid Function: What the Evidence Shows

Ashwagandha and thyroid function occupy an unusual space in the supplement literature: this is one of the few adaptogens where a direct effect on thyroid hormone levels has been measured as a primary endpoint in a published randomized controlled trial in humans — not inferred from mechanism or extrapolated from animal data. A 2018 RCT found that KSM-66 ashwagandha supplementation significantly raised both T3 (triiodothyronine) and T4 (thyroxine) levels and lowered TSH in adults with subclinical hypothyroidism over 8 weeks. The finding is clinically meaningful, but it immediately raises important questions: is this universally beneficial? Who should be cautious? What is the mechanism? And does this finding apply to thyroid-healthy individuals? This article answers those questions from the evidence available.

The Evidence Base

The primary human evidence on ashwagandha and thyroid function comes from a double-blind, randomized, placebo-controlled trial in 50 adults with subclinical hypothyroidism (defined as elevated TSH with normal T3/T4, representing early-stage or compensated thyroid underactivity). Subjects received either 600 mg/day of KSM-66 ashwagandha root extract or placebo for 8 weeks. The treatment group showed statistically significant increases in serum T3 and T4 levels compared to placebo, with a corresponding reduction in TSH — the pattern expected when thyroid hormone production normalizes. All changes remained within the normal physiological range, indicating a normalization effect in a subclinically hypothyroid population rather than supraphysiological stimulation.

The table below summarises clinical and mechanistic data on ashwagandha's interaction with thyroid hormones:

Study / Context	Dose	Population	Thyroid Effect	Clinical Note
Sharma et al., 2018 (RCT)	600 mg/day KSM-66	Subclinical hypothyroid adults	T3 up, T4 up, TSH normalised over 8 weeks	Promising; small sample (n=50)
General adaptogenic effect	300–600 mg/day	Stressed adults	Cortisol down → indirect TSH modulation	HPA–thyroid axis crosslink
Hyperthyroid / Graves' caution	Any dose	Hyperthyroid patients	May further elevate T3/T4 — risk of overstimulation	Avoid without physician oversight
Thyroid medication interaction	Any dose	Levothyroxine users	Potential additive effect; monitor TSH levels	Consult prescribing doctor

The broader stress and cortisol evidence from Chandrasekhar et al. (2012) — the most cited ashwagandha RCT, showing 27.9% reduction in serum cortisol — is directly relevant here. Chronic cortisol elevation suppresses the hypothalamic-pituitary-thyroid (HPT) axis through multiple mechanisms: it reduces TRH (thyrotropin-releasing hormone) secretion from the hypothalamus, impairs pituitary TSH response, and inhibits peripheral deiodinase enzymes that convert inactive T4 to active T3. If ashwagandha's thyroid effects are partly mediated through HPA axis normalization and cortisol reduction, its benefits would logically be most pronounced in stressed individuals with cortisol-driven thyroid suppression — which is common and often unrecognized.

Langade et al. (2019) confirmed these cortisol-reducing and sleep-improving effects in a separate RCT, strengthening the evidence for HPA axis normalization as a core pharmacological action of KSM-66 ashwagandha. Wankhede et al. (2015) demonstrated improved muscle strength and recovery in a trial of healthy adults doing resistance training — showing that ashwagandha has relevant effects in physically stressed populations. Choudhary et al. (2017) found cognitive improvements in adults with mild cognitive impairment, further supporting multi-system effects through stress hormone normalization.

Pratte et al. (2014), reviewing five human trials for anxiety specifically, noted consistent effects across studies that fit a picture of HPA axis normalization — relevant because the thyroid axis does not operate in isolation from the HPA axis. They share the hypothalamic-pituitary interface, and dysregulation in one system commonly affects the other.

The evidence gap: virtually all thyroid-specific human data comes from one trial in subclinical hypothyroid patients using KSM-66 at 600 mg/day. There is no RCT data on ashwagandha thyroid effects in euthyroid adults, in Hashimoto's disease, in those on levothyroxine, or in patients with hyperthyroidism. Extrapolating this finding to other populations is not supported by current evidence.

The Mechanism: HPA-HPT Axis Cross-Talk

Several mechanisms have been proposed for ashwagandha's effects on thyroid hormones, and they are not mutually exclusive. The best-supported involves axis cross-talk between the HPA and HPT systems.

Cortisol-mediated HPT axis suppression relief: Chronic HPA activation suppresses the HPT axis through at least three pathways. First, cortisol directly reduces TRH gene expression in the paraventricular nucleus of the hypothalamus, lowering the drive signal for TSH secretion. Second, cortisol impairs pituitary sensitivity to TRH, reducing TSH output per unit of TRH stimulus. Third, cortisol inhibits the type 2 deiodinase enzyme (D2) that converts T4 to the biologically active T3 in peripheral tissues, reducing effective thyroid hormone action even when T4 production is normal. Ashwagandha's consistent, well-replicated cortisol reduction in human trials — across multiple RCTs and study populations — would relieve all three points of suppression simultaneously. This is the most parsimonious explanation for the thyroid normalization finding in subclinical hypothyroid patients with presumably elevated stress burden.

Direct thyroid tissue effects: Withanolides — the primary steroidal lactone bioactives in ashwagandha — have been proposed to directly stimulate thyroid hormone synthesis through interactions with thyroid hormone receptors or upstream signaling. Evidence for this in humans is limited to the outcome data itself; no study has directly measured the molecular mechanism in human thyroid tissue. Animal studies have found withanolide effects on thyroid peroxidase activity and T4 synthesis in rodent thyroid tissue, but dose translation to human relevance is uncertain.

Antioxidant protection of thyroid tissue: Thyroid hormone synthesis requires hydrogen peroxide generated by dual oxidases (DUOX1/2) — an inherently oxidizing environment that makes the thyroid gland particularly susceptible to oxidative stress. Ashwagandha's antioxidant properties could theoretically protect thyroid cells from oxidative damage and maintain synthesis efficiency. This mechanism is plausible given the broader antioxidant evidence, but has not been tested in human thyroid tissue specifically.

Who Should Be Cautious: Important Safety Considerations

The finding that ashwagandha can raise thyroid hormone levels has significant clinical implications for specific populations where thyroid hormone elevation carries real risk:

People with hyperthyroidism or Graves' disease: Graves' disease is an autoimmune condition that drives excess thyroid hormone production. Symptoms include palpitations, tremor, heat intolerance, anxiety, weight loss, and in severe cases, thyroid storm — a life-threatening emergency. Any supplement that further raises thyroid hormone levels in this setting carries genuine clinical risk. Anyone with known or suspected hyperthyroidism should avoid ashwagandha until they have discussed it with their endocrinologist.

People on thyroid hormone replacement: Levothyroxine (T4) therapy is precisely dosed to keep TSH within a narrow therapeutic range. If ashwagandha independently raises endogenous T3/T4 production, it could push total levels above the therapeutic range and cause iatrogenic hyperthyroid symptoms, or complicate TSH interpretation at monitoring visits. Anyone on thyroid medication should consult their physician before starting ashwagandha and consider thyroid panel monitoring if they choose to proceed.

Hashimoto's thyroiditis: This is more nuanced. Hashimoto's causes progressive autoimmune destruction of thyroid tissue, leading to hypothyroidism. Ashwagandha's anti-inflammatory and cortisol-reducing effects could theoretically benefit Hashimoto's patients by reducing autoimmune drive. However, ashwagandha is a member of the Solanaceae family, and some integrative practitioners advise Hashimoto's patients to limit nightshade alkaloid exposure based on potential immune-stimulating effects. The direct evidence for this concern with ashwagandha specifically is weak, but the clinical caution is reasonable given the lack of Hashimoto's-specific trial data.

Pregnancy: Ashwagandha root has traditional use as an abortifacient at high doses in Ayurvedic medicine. Thyroid function is critically important during pregnancy for fetal neurological development and miscarriage prevention. Ashwagandha is generally contraindicated in pregnancy regardless of thyroid status.

Who Benefits Most

Based on available evidence, the populations with the clearest case for ashwagandha benefit in a thyroid context are:

• Adults with subclinical hypothyroidism and significant stress load: This is the exact population studied in the primary thyroid RCT. The stress-cortisol mechanism provides a plausible biological explanation for why effects are most pronounced here.
• People with chronic HPA axis dysregulation (high perceived stress, burnout, elevated cortisol): If thyroid suppression is partly cortisol-driven — which is common and measurable — then stress reduction from ashwagandha would benefit thyroid function as a downstream effect of HPA normalization.
• Athletes with high training loads: Overtraining syndrome suppresses thyroid function through elevated stress hormones and inflammatory cytokines. As documented in KSM-66 Clinical Trials, ashwagandha has shown benefits in athletic recovery and hormonal regulation under physical stress — the thyroid benefit may be part of this broader hormonal normalization effect.

It is worth emphasizing that normal, euthyroid individuals are not expected to develop hyperthyroid states from ashwagandha — the RCT found normalization of subclinical hypothyroid markers, not supraphysiological elevation. For euthyroid individuals, the thyroid-specific benefit is currently uncharacterized in clinical trials.

Practical Takeaways

• One RCT in subclinical hypothyroid adults confirms that 600 mg/day KSM-66 ashwagandha raised T3, T4, and lowered TSH over 8 weeks within physiological normal ranges. This is the primary human evidence.
• Anyone with hyperthyroidism, Graves' disease, or taking thyroid medication should consult an endocrinologist before using ashwagandha — the potential for clinically significant interaction is real.
• KSM-66 is the standardized root extract used in virtually all published human clinical trials, including the thyroid study. Formulations using whole root powder or undisclosed extracts may not replicate these findings. Bio:sudo KSM-66 Reishi Restore uses this extract at 600 mg/day, matching the trial dose.
• The cortisol reduction mechanism — well-established across multiple RCTs — provides a biologically coherent pathway for thyroid benefits in stressed individuals. Reducing HPA axis overactivation allows the HPT axis to normalize.
• Effects develop over 4–8 weeks of consistent use. The thyroid trial ran for 8 weeks; acute thyroid hormone changes from ashwagandha have not been reported.
• For broader hormonal context, see Ashwagandha Testosterone — ashwagandha has documented effects on multiple endocrine systems (cortisol, DHEA, testosterone, thyroid), and understanding the full hormonal picture helps set realistic expectations and identify interaction risks.

Bottom Line

The evidence for ashwagandha raising thyroid hormone levels is real — one well-designed RCT in subclinical hypothyroid adults demonstrates it clearly. The most plausible mechanism involves HPA-HPT axis cross-talk, with ashwagandha's established cortisol-reducing effects relieving a major point of suppression on the thyroid axis. But the finding comes with essential context: the benefit is established in a specific clinical population, thyroid hormone elevation from ashwagandha could be harmful in hyperthyroid individuals, and the data does not yet generalize to other thyroid conditions. For most users taking Bio:sudo KSM-66 Reishi Restore primarily for stress, sleep, and recovery — the most evidence-backed applications — the thyroid connection is relevant background knowledge rather than a direct therapeutic target. If thyroid function is a specific concern, get TSH and free T4 measured at baseline and after 8 weeks to see whether your levels respond. See Ashwagandha Cortisol Mechanism for the HPA axis mechanism that underlies most of ashwagandha's adaptogenic actions.

References

1. Chandrasekhar K, et al. "A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults." Indian J Psychol Med. 2012;34(3):255–262. [Source]
2. Langade D, et al. "Efficacy and safety of ashwagandha root extract in insomnia and anxiety." Medicine. 2019;98(37):e17186. [Source]
3. Wankhede S, et al. "Examining the effect of Withania somnifera supplementation on muscle strength and recovery." J Int Soc Sports Nutr. 2015;12:43. [Source]
4. Choudhary D, et al. "Efficacy and safety of ashwagandha root extract in improving memory and cognitive functions." J Dietary Suppl. 2017;14(6):599–612. [Source]
5. Pratte MA, et al. "An alternative treatment for anxiety: a systematic review of human trial results reported for the Ayurvedic herb ashwagandha." J Altern Complement Med. 2014;20(12):901–908. [Source]

---

---